E156: The Future of Clinical Trials, $18m Series A and Breaking Bottlenecks - Meri Beckwith (Co-founder Lindus Health)
In this week’s episode, Meri shares his journey from the world of investing to breaking the bottlenecks in clinical trials as he builds the anti-CRO for life science pioneers.
We discussed:
🔄 Transitioning from venture capital into healthtech 💼 Investor vs Founder Traits, Personality and Mindset 🌱 The origin story of Lindus Health 🏗️ The first few days/weeks of building Lindus Health 🚧 Barriers to entering the pharma industry as a new startup 🔒 Securing the first clinical trial with Habitual 🍾 The bottle necks of clinical trials 🔍 The process of recruiting patients for clinical trials ❌ Where central organisations and institutions go wrong for clinical trials 🤖 The role of AI in the pharma industry 💰 Fundraising a $18m Series A with investments from the likes of Peter Thiel 🔒 How to prevent being replaced by the board and investors 🏢 How to build a healthy culture and team 🤝 How to become a great CEO and deal with co-founder conflicts 💊 Why do pharma need CROs for clinical trials and why become the anti-CRO
Meri Beckwith is the co-founder of Lindus Health and previously a venture capital investor and partner to biotech and digital health companies. He took part in the COVID-19 vaccine trials as a volunteer, where he saw trail outcomes could be improved by focusing on patient experience.
-------------------------------------
Powered by Peerr
Peerr is a healthtech platform connecting the health and life sciences industry through content and thought leaders, KOLs and SMEs.
✍️ Publish articles or blogs, courses or offer coaching services 🗒 Over 250,000+ reads and 500+ articles-------------------------------------
YouTube:Amz & Abdul
Twitter -@ScrubbedIn_ Instagram - @Scrubbedin_
Weitere Episoden von „The Scrubbed In Show by Peerr“
Verpasse keine Episode von “The Scrubbed In Show by Peerr” und abonniere ihn in der kostenlosen GetPodcast App.